South Korea
Phyllodulcin Could be a Potential Candidate for Treating Alzheimer’s Disease, Find Sahmyook University Researchers
Assistant Professor Se Jin Jeon of the Department of Integrative Biotechnology, College of Science and Technology, Sahmyook University, along with a group of researchers from Korea, studied the effect of phyllodulcin on Aβ aggregation and various pathological features in an animal model of AD.
SK bioscience Releases 2023 ESG Report, Reaffirming Its Commitment to Sustainability
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, today released its 2023 Environmental, Social and Governance (ESG) Report.
PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Company's novel TIE2 agonistic antibody, in nAMD (neovascular age-related macular degeneration).
Samsung Biologics Reports Second Quarter 2023 Financial Results
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), today announced financial results for the second quarter of fiscal year 2023.
BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program
BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS), today announced receipt of the grand prize award in the 2023 Merck Advance Biotech Grant Program.
Neurophet to unveil brain image analysis technology related to treatment of Alzheimer’s disease at AAIC 2023
Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the Alzheimer's Association International Conference (AAIC) 2023, which is held in Amsterdam, Netherlands.
SK Biopharmaceuticals Makes Big Bets to be ‘Big Biotech’
SK Biopharmaceuticals' Chief Executive Officer Donghoon Lee presented the new vision at a press conference in Seoul, Tuesday, introducing its plan to globalize and mobilize its therapeutic modalities and platforms of radiopharmaceutical therapy (RPT)[1] and targeted protein degradation (TPD)[2].
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar
Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara® (Ustekinumab).
Samsung Bioepis Releases its Second US Biosimilar Market Report
Samsung Bioepis Co., Ltd. today released the second edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States.
Bridge Biotherapeutics Joins PROLIFIC, the Prognostic Lung Fibrosis Consortium
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation, announced that it has joined PROLIFIC, the Prognostic Lung Fibrosis Consortium, an organization devoted to boosting scientific exploration and drug development in pulmonary fibrosis.
